Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents
复制标题
DOI：
10.1007/s10549-010-1224-1
复制
发表时间：
2011-02-01
影响因子：
3.8
通讯作者：
Shepherd, Lois E.
中科院分区：
文献类型：
--
作者：
Goodwin, Pamela J.;Stambolic, Vuk;Shepherd, Lois E.
二甲双胍是一种廉价的口服药物，常用于治疗2型糖尿病，作为一种潜在的抗癌药物，已引起越来越多的关注。临床前、流行病学和临床证据表明，二甲双胍可降低总体癌症风险和死亡率，对乳腺癌有特异性作用。二甲双胍的广泛临床经验，加上其已知的（和适度的）毒性，使传统的药物评价过程得以缩短。我们回顾了一种改进的评估方法的基本原理，并概述了优化这种药物在乳腺癌中的发展的关键步骤，包括最近启动的III期辅助试验（NCIC MA.32）的讨论。
Metformin, an inexpensive oral agent commonly used to treat type 2 diabetes, has been garnering increasing attention as a potential anti-cancer agent. Preclinical, epidemiologic, and clinical evidences suggest that metformin may reduce overall cancer risk and mortality, with specific effects in breast cancer. The extensive clinical experience with metformin, coupled with its known (and modest) toxicity, has allowed the traditional process of drug evaluation to be shortened. We review the rationale for a modified approach to evaluation and outline the key steps that will optimize development of this agent in breast cancer, including discussion of a Phase III adjuvant trial (NCIC MA.32) that has recently been initiated.